Radio Blue Heart is on the air!

weird-ecologies:

saxifraga-x-urbium:

partisan-by-default:

saxifraga-x-urbium:

fucking livid

Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting amyloid proteins that form sticky plaques in the brains of Alzheimer’s disease patients. The drug had been particularly effective in animal models, and the trial results were eagerly awaited as one of the most promising treatments in years. It did not work. “Crenezumab did not slow or prevent cognitive decline” in people with a predisposition toward Alzheimer’s.

Last year, the Food and Drug Administration (FDA) narrowly approved the use of Aduhelm, a new drug from Biogen that the company has priced so highly that it’s expected to drive up the price of Medicare for everyone in America, even those who never need this drug. Aduhelm was the first drug to be approved that fights the accumulation of those “amyloid plaques” in the brain. What makes the approval of the $56,000-a-dose drug so controversial is that while it does decrease plaques, it doesn’t actually slow Alzheimer’s. In fact, clinical trials were suspended in 2019 after the treatment showed “no clinical benefits.” (Which did not keep Biogen from seeking the drug’s approval or pricing it astronomically.)

Over the last two decades, Alzheimer’s drugs have been notable mostly for having a 99% failure rate in human trials. It’s not unusual for drugs that are effective in vitro and in animal models to turn out to be less than successful when used in humans, but Alzheimer’s has a record that makes the batting average in other areas look like Hall of Fame material.

And now we have a good idea of why. Because it looks like the original paper that established the amyloid plaque model as the foundation of Alzheimer’s research over the last 16 years might not just be wrong, but a deliberate fraud.

thanks for the text extraction, i was on my phone <3

image

Jesus christ

  1. rappacheeks reblogged this from beatrice-otter
  2. most-definitively-a-human reblogged this from theorderofthetriad
  3. dancingcacti reblogged this from chalkrevelations
  4. siderewinders reblogged this from siderewinders
  5. queerwizarrds reblogged this from will-shut-up-4-wifi
  6. intenxty reblogged this from ejacutastic
  7. ease-out-the-clutch reblogged this from msbehavoyeur
  8. msbehavoyeur reblogged this from mosertone
  9. scp-bumblebee reblogged this from themboots
  10. themboots reblogged this from mosertone
  11. jupit7r reblogged this from mosertone
  12. left-the-porch reblogged this from mosertone
  13. chapelofthechimes reblogged this from niceofthenine
  14. weird-one-23 reblogged this from weird-one-23
  15. comradenidhogg reblogged this from komsomolka
  16. deodatasslawson reblogged this from komsomolka
  17. madain-sari reblogged this from eastofthemoon
  18. badwolfonthebay reblogged this from danteswornofkischou
  19. enchantedblackforest reblogged this from gettothestabbing
  20. ronjawood-thoughts reblogged this from gettothestabbing
  21. saxifraga-x-urbium posted this
    Last month, drug company Genentech reported on the first clinical trials of the drug crenezumab, a drug targeting...